3.95
price down icon0.13%   -0.010
 
loading

Inozyme Pharma Inc Aktie (INZY) Neueste Nachrichten

pulisher
May 22, 2025

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - Zacks Investment Research

May 22, 2025
pulisher
May 22, 2025

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN

May 22, 2025
pulisher
May 21, 2025

BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle

May 21, 2025
pulisher
May 21, 2025

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire

May 21, 2025
pulisher
May 21, 2025

BioMarin agrees to acquire Inozyme for $270m - MSN

May 21, 2025
pulisher
May 20, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

May 20, 2025
pulisher
May 19, 2025

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN

May 19, 2025
pulisher
May 19, 2025

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN

May 19, 2025
pulisher
May 19, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

May 19, 2025
pulisher
May 19, 2025

Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals

May 19, 2025
pulisher
May 19, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSETXNM), Servotronics, Inc. (NYSE AmericanSVT), Protagenic Therapeutics, Inc. (Nasdaq – - TradingView

May 19, 2025
pulisher
May 19, 2025

BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha

May 19, 2025
pulisher
May 19, 2025

Piper Sandler Downgrades Inozyme Pharma to Neutral From Overweight, Lowers Price Target to $4 From $23 - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

TD Cowen Downgrades Inozyme Pharma to Hold From Buy, Price Target is $4 - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Raymond James Downgrades Inozyme Pharma to Market Perform From Outperform - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

BioMarin to acquire Inozyme to enhance its enzyme therapy portfolio - World Pharmaceutical Frontiers

May 19, 2025
pulisher
May 18, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders - GlobeNewswire Inc.

May 18, 2025
pulisher
May 18, 2025

BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0

May 18, 2025
pulisher
May 18, 2025

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News

May 18, 2025
pulisher
May 18, 2025

The week in pharma: action, reaction and insight – week to May 16 - The Pharma Letter

May 18, 2025
pulisher
May 18, 2025

Wells Fargo & Company Reaffirms Equal Weight Rating for Inozyme Pharma (NASDAQ:INZY) - Defense World

May 18, 2025
pulisher
May 18, 2025

Inozyme Pharma (NASDAQ:INZY) Stock Rating Lowered by Wedbush - Defense World

May 18, 2025
pulisher
May 18, 2025

Inozyme Pharma (NASDAQ:INZY) Earns Hold Rating from Jefferies Financial Group - Defense World

May 18, 2025
pulisher
May 17, 2025

BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN

May 17, 2025
pulisher
May 17, 2025

Leerink bullish on BioMarin following Inozyme deal, expects additional BD - Yahoo Finance

May 17, 2025
pulisher
May 17, 2025

Wedbush Has Negative Outlook for Inozyme Pharma Q2 Earnings - Defense World

May 17, 2025
pulisher
May 16, 2025

Inozyme Pharma (INZY) Downgraded by Needham Analyst | INZY Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Inozyme downgraded to Hold from Buy at TD Cowen - TipRanks

May 16, 2025
pulisher
May 16, 2025

BioMarin to acquire Inozyme for $270 million By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Inozyme Pharma (INZY) Downgraded by Wells Fargo | INZY Stock New - GuruFocus

May 16, 2025
pulisher
May 16, 2025

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business - insights.citeline.com

May 16, 2025
pulisher
May 16, 2025

Inozyme Pharma (INZY) Downgraded by Wells Fargo | INZY Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Inozyme (INZY) Downgraded Following Acquisition Deal | INZY Stoc - GuruFocus

May 16, 2025
pulisher
May 16, 2025

TD Cowen cuts Inozyme stock rating post-acquisition news - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

TD Cowen cuts Inozyme stock rating post-acquisition news By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Biomarin snags potential ‘first-in-disease’ ERT in $270M Inozyme buy - BioWorld MedTech

May 16, 2025
pulisher
May 16, 2025

BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease - MedCity News

May 16, 2025
pulisher
May 16, 2025

Inozyme Pharma (INZY) Sees Price Target Slash and Downgrade by J - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Inozyme Pharma’s Strategic Acquisition by Biomarin: Analyst Holds Rating Amid Favorable Shareholder Outcome and Strategic Alignment - TipRanks

May 16, 2025
pulisher
May 16, 2025

Inozyme (INZY) Downgraded Following Acquisition by BioMarin | INZY Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Dollar Stock Skyrockets 179% On BioMarin Takeover - Investor's Business Daily

May 16, 2025
pulisher
May 16, 2025

BioMarin stock rises following Inozyme Pharma acquisition By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

BioMarin stock rises following Inozyme Pharma acquisition - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M - TipRanks

May 16, 2025
pulisher
May 16, 2025

Jefferies Downgrades Inozyme Pharma to Neutral From Buy - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

BioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market Challenges - TipRanks

May 16, 2025
pulisher
May 16, 2025

Jefferies Downgrades Inozyme (INZY) After Acquisition Announceme - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Jefferies Downgrades Inozyme (INZY) After Acquisition Announcement | INZY Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Inozyme downgraded to Hold from Buy at Jefferies - TipRanks

May 16, 2025
pulisher
May 16, 2025

Cooley, Goodwin Build BioMarin's $270M Inozyme Buy - Law360

May 16, 2025
pulisher
May 16, 2025

BioMarin grows enzyme portfolio with $270M Inozyme buy - FirstWord Pharma

May 16, 2025
pulisher
May 16, 2025

BioMarin (BMRN) Set to Acquire Inozyme Pharma for $270M | BMRN Stock News - GuruFocus

May 16, 2025
$1.16
price down icon 17.27%
$31.18
price down icon 3.94%
$578.71
price down icon 0.54%
$286.89
price down icon 0.52%
$4.10
price down icon 2.24%
$72.94
price down icon 0.11%
Kapitalisierung:     |  Volumen (24h):